Durable Responses and Sustained Low Disease Activity Over Nine Months After a Single Dose of Mesoblast Cell Therapy in Rheumatoid Arthritis Patients Resistant to Anti-TNF Agents
Biz Wire Express,
GlobeNewswire 2017-02-15 Mesoblast Chief Executive Silviu Itescu commented: “The nine-month outcomes generated from this study…